Spera Pharma

Spera Pharma is a prominent Japanese Contract Development and Manufacturing Organization (CDMO) specializing in CMC (Chemistry, Manufacturing, and Controls) services. The company was established in 2017 as a spin-off from the CMC division of Takeda Pharmaceutical Company, inheriting a wealth of technical expertise and state-of-the-art facilities. Its core service offerings include drug substance development, formulation research, and analytical development for both clinical and commercial stages. Spera Pharma is particularly recognized for its capabilities in small molecule synthesis, peptide development, and complex formulation challenges. In 2023, the company was acquired by Bushu Pharmaceuticals, creating one of the largest CDMO groups in Japan. The organization operates primarily out of its headquarters and research facilities in Osaka, supporting a global client base in the pharmaceutical and biotech sectors.